Prostate cancer is the second most common cancer in American men. While the disease is prevalent across the country, the screening guidelines are not. Prostate cancer screenings have always been somewhat controversial because the tests often alert physicians to the presence of cancer, but there is no precise way to determine, definitively, whether the cancer […]
On average, women live longer than men and researchers estimate that the gap in longevity will continue. According to the U.S. Census Bureau, women’s life expectancy is projected to reach 87.3 years by 2060, compared with 83.9 years for men. There are a few factors while the mortality rate for men is higher, but overall, […]
As the COVID-19 pandemic continues, many cancer patients are having to make the difficult decision to continue with their current cancer regimen or delay treatments. Cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the risk of COVID-19. To help ease these decisions, several peer-reviewed, non-profit cancer care organizations […]
When deciding which treatment option is best for their prostate cancer, men take numerous factors into consideration. While their physician’s recommendation does play an important role in the treatment decision, in the end, most men make the choice that is best for them. That choice is often based on treatment outcomes and side effects, and […]
Accuray Incorporated, developer and manufacturer of the CyberKnife® System, announced that published data from two multicenter studies using differing protocols provide consistent results and reinforce the use of the CyberKnife system for the effective management of low-and intermediate-risk prostate cancer. The studies are the largest conducted to date evaluating stereotactic body radiation therapy (SBRT) in […]
Accuray, the company that develops and manufactures the CyberKnife® Robotic Radiosurgery System, the system that New Jersey CyberKnife uses to treat cancer, recently announced the results of the first study that evaluated the use of stereotactic body radiation therapy (SBRT) in low-risk prostate cancer 10 years post treatment. The study titled, “Stereotactic Body Radiotherapy for […]
Last week, the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) released collaborative clinical guidelines for managing localized prostate cancer which offers a framework for shared decision-making between physicians and patients. Through this collaboration, the committee provided guidance on active surveillance and on which treatments […]
